We are live on ! Find out more
SCNI

Scinai Immunotherapeutics
SCNI

7 hedge funds and large institutions have $58.4K invested in Scinai Immunotherapeutics in 2025 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

17% more funds holding

Funds holding: 6 → 7 (+1)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

0.22% less ownership

Funds ownership: 0.48% → 0.26% (-0.22%)

4% less capital invested

Capital invested by funds: $60.9K → $58.4K (-$2.5K)

Holders
7
Holders Change
+1
Holders Change %
+16.67%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
XT
XTX Topco
Cayman Islands
+$31.1K
2
VF
Virtu Financial
New York
+$17.6K
3
Citadel Advisors
Citadel Advisors
Florida
+$6.76K
4
UBS Group
UBS Group
Switzerland
+$1.98K

Top Sellers

Rank Fund Capital Flow
1
TSS
Two Sigma Securities
New York
-$18.6K
2
RhumbLine Advisers
RhumbLine Advisers
Massachusetts
-$1.9K
3
Morgan Stanley
Morgan Stanley
New York
-$217

SCNI Hedge Fund Activity: Q4 2025 in Review

7 of the 8,270 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q4 2025, worth a combined $58.4K — down 4.1% from $60.9K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new SCNI positions and 1 closed out — a net gain of 1 holder — while 2 added to existing stakes and 2 trimmed.

The largest buyer was XTX Topco, opening a new position worth an estimated $31.1K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $18.6K sold.

  • 7 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q4 2025, up from 6 in Q3 2025.
  • Funds reported $58.4K of Scinai Immunotherapeutics stock for Q4 2025, down 4.1% quarter-over-quarter.
  • 2 funds opened new Scinai Immunotherapeutics positions in Q4 2025 and 1 closed out, a net change of +1 holder.
  • The largest Scinai Immunotherapeutics buyer in Q4 2025 was XTX Topco, an estimated $31.1K added.
  • The largest Scinai Immunotherapeutics seller in Q4 2025 was Two Sigma Securities, an estimated $18.6K sold.

Based on aggregated 13F filings for Q4 2025.